Thermo Fisher’s board of directors have approved a definitive agreement to acquire PPD for $17.4 billion plus an assumption of about $3.5 billion of net debt, according to a news release.
PPD is a company that tests experimental prescription drugs and provides lab services. Thermo Fisher said it generated a revenue of $4.7 billion in 2020. It’s set to become a part of Thermo’s laboratory products and services segment.
The transaction is expected to be completed by the end of 2021.
Read the full news release here.
More articles on supply chain:
51 best hospital, health system supply chains in North America, per GHX
Shortage of plastic growbags threatens global vaccine supply
Intermountain signs 10-year contract with Vizient
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.